Old Web
English
Sign In
Acemap
>
authorDetail
>
Helene Vioix
Helene Vioix
Merck KGaA
Medicine
Exon
Internal medicine
non small cell
Lung cancer
4
Papers
1
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Financial impact of tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer bearing METex14 skipping in the United States.
2021
Journal of Clinical Oncology
Matthew Stargardter
Mo Yang
Jon Tosh
Apoorva Ambavane
Madhav Mittal
Helene Vioix
Frank Xiaoqing Liu
Ali McBride
Show All
Source
Cite
Save
Citations (0)
U.S. health utility in advanced non-small cell lung cancer (NSCLC) patients harboring MET exon 14 (METex14) skipping mutations treated with tepotinib.
2021
Journal of Clinical Oncology
Paul K. Paik
Mo Yang
Emma S. Knowles
Anthony J. Hatswell
Helene Vioix
Frank Xiaoqing Liu
Show All
Source
Cite
Save
Citations (0)
Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring METex14 skipping alterations in the United States.
2021
Journal of Medical Economics
Matthew Stargardter
Ali McBride
Jon Tosh
Rameet Sachdev
Mo Yang
Apoorva Ambavane
Madhav Mittal
Helene Vioix
Frank Xiaoqing Liu
Show All
Source
Cite
Save
Citations (1)
Tepotinib in patients (pts) with NSCLC with MET exon 14 (METex14) skipping: Health-related quality of life (HRQoL).
2020
Journal of Clinical Oncology
Paul K. Paik
Leora Horn
Dariusz M. Kowalski
Jyoti D. Patel
Frank Griesinger
Ji Youn Han
Egbert F. Smit
Terufumi Kato
Xiuning Le
Jürgen Scheele
R. Bruns
Helene Vioix
Boris M. Pfeiffer
Byoung Chul Cho
Show All
Source
Cite
Save
Citations (0)
1